developing Drugs from targets or small molecules & securing funding

This week, we welcome Emeritus Professor Maree Smith to TRI along with Dr Stuart Newman, CEO of Therapeutic Innovation Australia (TIA). Together they will explain how you go about developing new therapeutic products suitable for clinical trials from your biological target or small molecule. Stuart will also talk about the funding and support which is available through the TIA. This is an unique opportunity to tap into Maree's drug development expertise, which includes developing a neuropathic pain killer that was acquired by Novartis in 2015 following early phase clinical trials as well as creating TetraQ, which is recognised as a GLP-accredited drug development Centre in Australia.

 This seminar is part of the TRI Research Translation Committee's weekly Tuesday lunchtime series. This series is a must for any researcher interested in research translation, as the short and sharp seminars are designed to provide case studies on entrepreneurial and translational research projects and the role of partners (such as clinicians, patients, industry and funding agencies) in the success of these projects. 

 Zoom recording